pirtobrutinib,rituximab,venetoclax
roche,eli lilly,abbvie
['bruin study', 'fil,veral,12', 'pirto', 'bruin', 'lymsm', 'valent ,(-prevalent),(-equivalent),(-bivalent)', 'valent ,(-prevalent)']
congress | #ash22 discusses results of the phase i/ii bruin study of the btk inhibitor pirtobrutinib in r/r #wm. the drug was shown to be highly active and well-tolerated, irrespective of prior therapy status. #lymsm #medicalcongress #hematology 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm